Christian Waage Appointed General Counsel of Receptos
November 26 2013 - 8:00AM
Receptos, Inc. (Nasdaq:RCPT) announced today that Christian Waage
has been appointed Senior Vice President and General Counsel of the
Company.
Mr. Waage joins Receptos from Websense Inc., where he served as
Vice President and General Counsel from 2012 until its acquisition
in 2013. Prior to Websense, he served as Vice President and General
Counsel of Ardea Biosciences from 2008 until its acquisition in
2012. Prior to Ardea Biosciences, Mr. Waage practiced law for over
a decade at DLA Piper, where he was a Partner. He received a
JD from the University of San Diego School of Law and a Bachelor's
degree in Economics from the University of California, San
Diego.
"Christian brings tremendous legal experience both in the
biotechnology sector and more broadly," said Faheem Hasnain,
President and Chief Executive Officer of Receptos. "Christian's
leadership and guidance will support our efforts as we execute on
our development programs, including our ongoing Phase 2/3 study of
RPC1063 in relapsing multiple sclerosis as well as our Phase 2
study in ulcerative colitis."
Added Mr. Waage, "I see a great deal of promise in Receptos'
pipeline of therapeutics as well as its skilled leadership team.
Receptos is a fast-moving company with a history of strong
execution, and I look forward to our evolution into a late-stage
clinical development organization."
Forward-Looking Statements
Statements contained in this release, other than statements of
historical fact, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of
1995. The words "expects," "believes," "anticipates," "may,"
"intends," "plans," "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements do not constitute guarantees of future
performance. Investors are cautioned that forward-looking
statements, including without limitation statements regarding
development and future potential of the Company's product
candidates, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated. These forward-looking statements are
based upon the Company's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include without limitation risks associated with the process of
discovering, developing and commercializing drug candidates that
are safe and effective for use as human therapeutics. These
and other risks regarding the Company's financial position and
research and development programs are described in detail in the
Company's SEC filings, including the Company's Quarterly Reports on
Form 10-Q and the Registration Statement on Form S-1 which was
declared effective on May 8, 2013. All forward-looking
statements contained in this release speak only as of the date on
which they were first made by the Company, and the Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after such date.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic
candidates for the treatment of immune and metabolic diseases. The
Company's lead program, RPC1063, is a sphingosine 1-phosphate 1
receptor (S1P1R) small molecule modulator candidate for immune
indications, including relapsing multiple sclerosis (RMS) and
inflammatory bowel disease (IBD). The Company is also developing
RPC4046, an anti-interleukin-13 (IL-13) antibody for an
allergic/immune-mediated orphan disease, eosinophilic esophagitis
(EoE). Receptos has established expertise in high resolution
protein crystal structure determination, biology and drug discovery
for G-protein-coupled receptors (GPCRs).
CONTACT: Media and Investor Contacts:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
mrice@lifesciadvisors.com
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Sep 2024 to Oct 2024
RECEPTOS, INC. (NASDAQ:RCPT)
Historical Stock Chart
From Oct 2023 to Oct 2024